Giampaolo Talamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giampaolo Talamo has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Jozef Malysz
Department of Pathology, Milton S. Hershey Cancer Institute, Penn State University, Hershey, PA
6 shared publicationsMaurizio Zangari
Blood/Marrow and Myeloma Program University of Utah Salt Lake City UT USA
5 shared publicationsJunjia Zhu
Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
4 shared publicationsManoj K. Pandey
Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
4 shared publications- Muhammad Ayaz Mir
Penn State Hershey Cancer Institute, Hershey, PA
4 shared publications Jason Liao
3 shared publications
Latest Publications
- 1 December 2018
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (12) , e515-e519
Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma
- 1 December 2018
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (12) , e515-e519
Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e19504
Outcomes of G-CSF alone vs G-CSF with upfront plerixafor vs G-CSF/chemotherapy for collection of autologous stem cells in patients with multiple myeloma.
E19504 Background: Strategies for optimizing the collection of peripheral blood stem cells (PBSC) for autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) vary among transplant centers, and include the use of G-CSF alone or in combination with plerixafor, or mobilization chemotherapy + G-CSF. In 2010, we started using “upfront” plerixafor, given on the day before the PBSC collection. Methods:We retrospectively analyzed the outcomes of 423 consecutive MM patients who underwent PBSC collections at the Penn State Hershey Cancer Institute. PBSC were collected after mobilization chemotherapy + G-CSF 5 mcg/Kg/day (group A, 91 pts), G-CSF alone, 10-16 mcg/Kg/day (group B, 72 pts), and G-CSF with “upfront” plerixafor 0.16-0.24 mg/Kg on the day before the stem cell collection (group C, 245 pts). Fifteen patients were excluded from the analysis because they collected with chemotherapy + plerixafor, received pegylated G-CSF, or plerixafor “on demand”, i.e., after failure to achieve an adequate number of stem cells on the first day of collection. We compared yields, number of days required for apheresis, clinical outcomes, and adverse events among these groups. Results: The median number of PBSC collected was 16.4 (range, 0.1-134), 4.2 (range, 0-12), and 6.2 (range, 0.2-41.2) million CD34+ cells/Kg in group A, B, and C, respectively (p+cells/Kg, was observed in 5 (5.5%), 9 (12.5%), and 15 (6.1%) patients of group A, B, and C, respectively (p<0.001). Twenty patients in group A developed neutropenic fever requiring hospital admission, and 1 of them died of septic shock, whereas no mortality was observed in groups B or C. No difference in the rapidity of PBSC engraftment, progression-free survival, and overall survival was observed among the 3 groups. Conclusions:In patients with MM, the upfront use of plerixafor with G-CSF provided the best collection strategy: it avoided the morbidity and mortality associated with the mobilization chemotherapy, and it provided higher yields than G-CSF alone.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e19504
Outcomes of G-CSF alone vs G-CSF with upfront plerixafor vs G-CSF/chemotherapy for collection of autologous stem cells in patients with multiple myeloma.
E19504 Background: Strategies for optimizing the collection of peripheral blood stem cells (PBSC) for autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) vary among transplant centers, and include the use of G-CSF alone or in combination with plerixafor, or mobilization chemotherapy + G-CSF. In 2010, we started using “upfront” plerixafor, given on the day before the PBSC collection. Methods:We retrospectively analyzed the outcomes of 423 consecutive MM patients who underwent PBSC collections at the Penn State Hershey Cancer Institute. PBSC were collected after mobilization chemotherapy + G-CSF 5 mcg/Kg/day (group A, 91 pts), G-CSF alone, 10-16 mcg/Kg/day (group B, 72 pts), and G-CSF with “upfront” plerixafor 0.16-0.24 mg/Kg on the day before the stem cell collection (group C, 245 pts). Fifteen patients were excluded from the analysis because they collected with chemotherapy + plerixafor, received pegylated G-CSF, or plerixafor “on demand”, i.e., after failure to achieve an adequate number of stem cells on the first day of collection. We compared yields, number of days required for apheresis, clinical outcomes, and adverse events among these groups. Results: The median number of PBSC collected was 16.4 (range, 0.1-134), 4.2 (range, 0-12), and 6.2 (range, 0.2-41.2) million CD34+ cells/Kg in group A, B, and C, respectively (p+cells/Kg, was observed in 5 (5.5%), 9 (12.5%), and 15 (6.1%) patients of group A, B, and C, respectively (p<0.001). Twenty patients in group A developed neutropenic fever requiring hospital admission, and 1 of them died of septic shock, whereas no mortality was observed in groups B or C. No difference in the rapidity of PBSC engraftment, progression-free survival, and overall survival was observed among the 3 groups. Conclusions:In patients with MM, the upfront use of plerixafor with G-CSF provided the best collection strategy: it avoided the morbidity and mortality associated with the mobilization chemotherapy, and it provided higher yields than G-CSF alone.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3023
Overall survival in patients with metastatic melanoma treated with concurrent ipilimumab and radiotherapy.
3023 Background: There is a growing body of evidence supporting the complementary roles of radiation therapy and immunotherapy in the treatment of malignancy. The mechanism of this phenomenon is unclear, but is thought to be mediated by synergistic mechanisms of immune activation. Ipilimumab (Ipi) is a monoclonal antibody used in the treatment of malignant melanoma that inhibits cytotoxic T-Lymphocyte antigen 4 (CTLA-4), an immunologic checkpoint on T cells. There are a few small studies suggesting an interaction between ipilimumab and radiation therapy, but larger systematic studies supporting these observations are limited. Methods: We conducted a retrospective analysis to evaluate all patients treated with ipilimumab for metastatic melanoma at a single institution from May 2011 to June 2015. Patients were grouped into those that had received concurrent radiation therapy while on ipilimumab (Ipi-RT) treatment, and those who did not. We then evaluated the treatment response following completion of ipilimumab. Primary outcome measured was rate of complete response (CR) in both radiated and distant disease sites, measured by RECIST criteria. Secondary outcome measures included ORR and OS. Results: A total of 101 patients received ipilimumab in the prespecified time frame. Seventy received Ipi-RT and 31 received ipilimumab without concurrent RT. Among the 70 who received Ipi-RT, 18 (25.7%) achieved a CR, compared to 2 out of 29 (6.45%) in the Ipi alone group [Odds ratio 5.02 (95%CI 1.09-23.2), p = 0.04]. Median OS was significantly increased in the concurrent Ipi-RT arm at 21 months vs 10 months for Ipi alone (p = 0.025). Conclusions: Patients treated with concurrent ipilimumab plus radiation therapy had a statistically significant increase in rates of complete response and median OS than those treated with ipilimumab alone. Prospective studies are needed to validate these findings.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3023
Overall survival in patients with metastatic melanoma treated with concurrent ipilimumab and radiotherapy.
3023 Background: There is a growing body of evidence supporting the complementary roles of radiation therapy and immunotherapy in the treatment of malignancy. The mechanism of this phenomenon is unclear, but is thought to be mediated by synergistic mechanisms of immune activation. Ipilimumab (Ipi) is a monoclonal antibody used in the treatment of malignant melanoma that inhibits cytotoxic T-Lymphocyte antigen 4 (CTLA-4), an immunologic checkpoint on T cells. There are a few small studies suggesting an interaction between ipilimumab and radiation therapy, but larger systematic studies supporting these observations are limited. Methods: We conducted a retrospective analysis to evaluate all patients treated with ipilimumab for metastatic melanoma at a single institution from May 2011 to June 2015. Patients were grouped into those that had received concurrent radiation therapy while on ipilimumab (Ipi-RT) treatment, and those who did not. We then evaluated the treatment response following completion of ipilimumab. Primary outcome measured was rate of complete response (CR) in both radiated and distant disease sites, measured by RECIST criteria. Secondary outcome measures included ORR and OS. Results: A total of 101 patients received ipilimumab in the prespecified time frame. Seventy received Ipi-RT and 31 received ipilimumab without concurrent RT. Among the 70 who received Ipi-RT, 18 (25.7%) achieved a CR, compared to 2 out of 29 (6.45%) in the Ipi alone group [Odds ratio 5.02 (95%CI 1.09-23.2), p = 0.04]. Median OS was significantly increased in the concurrent Ipi-RT arm at 21 months vs 10 months for Ipi alone (p = 0.025). Conclusions: Patients treated with concurrent ipilimumab plus radiation therapy had a statistically significant increase in rates of complete response and median OS than those treated with ipilimumab alone. Prospective studies are needed to validate these findings.
- Open Access
- 18 February 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 40
Current Role of Radiation Therapy for Multiple Myeloma
BACKGROUND: Radiation therapy (RT) is a treatment modality traditionally used in patients with multiple myeloma (MM), but little is known regarding the role and effectiveness of RT in the era of novel agents, i.e, immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). METHODS: We retrospectively reviewed data from 449 consecutive MM patients seen at our institute in 2010-12 to assess indications for RT as well as its effectiveness. Pain response was scored similarly to RTOG 0631 and used the numerical rating pain scale (NRPS). RESULTS: Among 442 evaluable patients, 149 (34%) patients and 262 sites received RT. The most common indication for RT was palliation of bone pain (n=109, 42%), followed by prevention/treatment of pathological fractures (n=73, 28%), spinal cord compression (n=26, 10%), and involvement of vital organs/extramedullary disease (n=25, 10%). Of the 55 patients evaluable for pain relief, complete and partial responses were obtained in 76.4% and 7.2% respectively. Prior RT did not significantly decrease the median number of peripheral blood stem cells collected for autologous transplant, even when prior RT was given to both the spine and pelvis. Inadequacy of stem cell collection for autologous stem cell transplant (ASCT) was not significantly different and it occurred in 9% and 15% of patients receiving no RT and spine/pelvic RT, respectively. None of the 3 cases of therapy-induced AML/MDS occurred in the RT group. CONCLUSIONS: Despite the introduction of novel effective agents in the treatment of MM, RT remains a major therapeutic component for the management in 34% of patients, and it effectively provides pain relief while not interfering with successful peripheral blood stem cell collection for ASCT.
- 18 February 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 40
Open AccessCurrent Role of Radiation Therapy for Multiple Myeloma
BACKGROUND: Radiation therapy (RT) is a treatment modality traditionally used in patients with multiple myeloma (MM), but little is known regarding the role and effectiveness of RT in the era of novel agents, i.e, immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). METHODS: We retrospectively reviewed data from 449 consecutive MM patients seen at our institute in 2010-12 to assess indications for RT as well as its effectiveness. Pain response was scored similarly to RTOG 0631 and used the numerical rating pain scale (NRPS). RESULTS: Among 442 evaluable patients, 149 (34%) patients and 262 sites received RT. The most common indication for RT was palliation of bone pain (n=109, 42%), followed by prevention/treatment of pathological fractures (n=73, 28%), spinal cord compression (n=26, 10%), and involvement of vital organs/extramedullary disease (n=25, 10%). Of the 55 patients evaluable for pain relief, complete and partial responses were obtained in 76.4% and 7.2% respectively. Prior RT did not significantly decrease the median number of peripheral blood stem cells collected for autologous transplant, even when prior RT was given to both the spine and pelvis. Inadequacy of stem cell collection for autologous stem cell transplant (ASCT) was not significantly different and it occurred in 9% and 15% of patients receiving no RT and spine/pelvic RT, respectively. None of the 3 cases of therapy-induced AML/MDS occurred in the RT group. CONCLUSIONS: Despite the introduction of novel effective agents in the treatment of MM, RT remains a major therapeutic component for the management in 34% of patients, and it effectively provides pain relief while not interfering with successful peripheral blood stem cell collection for ASCT.
- 10 February 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (5) , 521-522
Effect of Topical Vaginal Androgens in a Woman on the Testosterone Levels of Her Sexual Partner With Prostate Cancer
- 10 February 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (5) , 521-522
Effect of Topical Vaginal Androgens in a Woman on the Testosterone Levels of Her Sexual Partner With Prostate Cancer
- Open Access
- 1 February 2015
- Published by SAGE Publications in Rare Tumors
- Vol. 7 (1) , 16-19
Estimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples
Measurement of daily proteinuria in patients with amyloidosis is recommended at the time of diagnosis for assessing renal involvement, and for monitoring disease activity. Renal involvement is usually defined by proteinuria >500 mg/day. We evaluated the accuracy of the random urine protein-to-creatinine ratio (Pr/Cr) in predicting 24 hour proteinuria in patient with amyloidosis. We compared results of random urine Pr/Cr ratio and concomitant 24-hour urine collections in 44 patients with amyloidosis. We found a strong correlation (Spearman's ρ=0.874) between the Pr/Cr ratio and the 24 hour urine protein excretion. For predicting renal involvement, the optimal cut-off point of the Pr/Cr ratio was 715 mg/g. The sensitivity and specificity for this point were 91.8% and 95.5%, respectively, and the area under the curve value was 97.4%. We conclude that the random urine Pr/Cr ratio could be useful in the screening of renal involvement in patients with amyloidosis. If validated in a prospective study, the random urine Pr/Cr ratio could replace the 24 hour urine collection for the assessment of daily proteinuria and presence of nephrotic syndrome in patients with amyloidosis.
- 1 February 2015
- Published by SAGE Publications in Rare Tumors
- Vol. 7 (1) , 16-19
Open AccessEstimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples
Measurement of daily proteinuria in patients with amyloidosis is recommended at the time of diagnosis for assessing renal involvement, and for monitoring disease activity. Renal involvement is usually defined by proteinuria >500 mg/day. We evaluated the accuracy of the random urine protein-to-creatinine ratio (Pr/Cr) in predicting 24 hour proteinuria in patient with amyloidosis. We compared results of random urine Pr/Cr ratio and concomitant 24-hour urine collections in 44 patients with amyloidosis. We found a strong correlation (Spearman's ρ=0.874) between the Pr/Cr ratio and the 24 hour urine protein excretion. For predicting renal involvement, the optimal cut-off point of the Pr/Cr ratio was 715 mg/g. The sensitivity and specificity for this point were 91.8% and 95.5%, respectively, and the area under the curve value was 97.4%. We conclude that the random urine Pr/Cr ratio could be useful in the screening of renal involvement in patients with amyloidosis. If validated in a prospective study, the random urine Pr/Cr ratio could replace the 24 hour urine collection for the assessment of daily proteinuria and presence of nephrotic syndrome in patients with amyloidosis.
- Open Access
- 1 February 2015
- Published by MDPI AG in Hematology Reports
- Vol. 7 (1) , 5704
Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
- 1 February 2015
- Published by MDPI AG in Hematology Reports
- Vol. 7 (1) , 5704
Open AccessCentral Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
- 10 January 2015
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (6) , 1011-1016
IgM MGUS associated with anti-MAG neuropathy: a single institution experience
Anti-MAG neuropathy is a very rare form of acquired polyneuropathy associated with IgM monoclonal gammopathy of undetermined significance (MGUS). We conducted a retrospective review of 194 consecutive MGUS patients seen at the Penn State Hershey Cancer Institute. We identified six patients among 37 (16 %) with IgM MGUS with anti-MAG neuropathy. Interestingly, an additional patient had anti-MAG neuropathy without MGUS. Common clinical manifestations were numbness and paresthesias of the extremities and gait imbalance. All four patients treated with rituximab and none of the three untreated ones had a subjective improvement of their symptoms. We conclude that all patients with IgM MGUS and neuropathy should be screened for anti-MAG antibodies and, if positive, they should be offered treatment with rituximab.
- 10 January 2015
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (6) , 1011-1016
IgM MGUS associated with anti-MAG neuropathy: a single institution experience
Anti-MAG neuropathy is a very rare form of acquired polyneuropathy associated with IgM monoclonal gammopathy of undetermined significance (MGUS). We conducted a retrospective review of 194 consecutive MGUS patients seen at the Penn State Hershey Cancer Institute. We identified six patients among 37 (16 %) with IgM MGUS with anti-MAG neuropathy. Interestingly, an additional patient had anti-MAG neuropathy without MGUS. Common clinical manifestations were numbness and paresthesias of the extremities and gait imbalance. All four patients treated with rituximab and none of the three untreated ones had a subjective improvement of their symptoms. We conclude that all patients with IgM MGUS and neuropathy should be screened for anti-MAG antibodies and, if positive, they should be offered treatment with rituximab.
- 15 December 2014
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 22 (2) , 332-334
Bortezomib-induced acute pancreatitis: Case report and review of the literature
Acute pancreatitis is a rare complication of chemotherapy agents. We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, a proteasome inhibitor commonly used in the treatment of this disease. We reviewed the available medical literature on this topic, and found other seven similar cases, all after intravenous bortezomib. Our case is the first one occurring with the subcutaneous route of administration.
- 15 December 2014
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 22 (2) , 332-334
Bortezomib-induced acute pancreatitis: Case report and review of the literature
Acute pancreatitis is a rare complication of chemotherapy agents. We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, a proteasome inhibitor commonly used in the treatment of this disease. We reviewed the available medical literature on this topic, and found other seven similar cases, all after intravenous bortezomib. Our case is the first one occurring with the subcutaneous route of administration.
- Open Access
- 1 August 2012
- Published by SAGE Publications in Rare Tumors
- Vol. 4 (3) , 123-126
Clinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, are limited. We retrospectively reviewed clinical outcomes, response to therapy, and survival of 17 patients seen at the Penn State Hershey Cancer Institute since the availability of novel agents (2006–2011). Twelve patients had primary PCL (pPCL), and 5 secondary PCL (sPCL). PCL was associated with aggressive clinicobiological features, such as high-risk cytogenetics, elevated serum beta-2-microglobulin and lactate dehydrogenase, International Staging System stage III, and rapid relapse after therapy. With the use of thalidomide, lenalidomide, and bortezomib in 53%, 53%, and 88% patients, respectively, median overall survival (OS) was 18 months in the whole group (95% confidence interval, 11–21 months), and 21 and 4 months in pPCL and sPCL, respectively (P=0.015). OS was inferior to that of 313 consecutive patients with multiple myeloma (MM) treated in the same period, even when compared with a subset of 47 MM with high-risk cytogenetics. Although our data are limited by the small sample size, we conclude that novel agents may modestly improve survival in patients with PCL, when compared to historical controls. Novel therapies do not seem to overcome the negative prognosis of PCL as compared with MM.
- 1 August 2012
- Published by SAGE Publications in Rare Tumors
- Vol. 4 (3) , 123-126
Open AccessClinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, are limited. We retrospectively reviewed clinical outcomes, response to therapy, and survival of 17 patients seen at the Penn State Hershey Cancer Institute since the availability of novel agents (2006–2011). Twelve patients had primary PCL (pPCL), and 5 secondary PCL (sPCL). PCL was associated with aggressive clinicobiological features, such as high-risk cytogenetics, elevated serum beta-2-microglobulin and lactate dehydrogenase, International Staging System stage III, and rapid relapse after therapy. With the use of thalidomide, lenalidomide, and bortezomib in 53%, 53%, and 88% patients, respectively, median overall survival (OS) was 18 months in the whole group (95% confidence interval, 11–21 months), and 21 and 4 months in pPCL and sPCL, respectively (P=0.015). OS was inferior to that of 313 consecutive patients with multiple myeloma (MM) treated in the same period, even when compared with a subset of 47 MM with high-risk cytogenetics. Although our data are limited by the small sample size, we conclude that novel agents may modestly improve survival in patients with PCL, when compared to historical controls. Novel therapies do not seem to overcome the negative prognosis of PCL as compared with MM.